Hasegawa Masayuki, Nelson Heather H, Peters Edward, Ringstrom Elin, Posner Marshall, Kelsey Karl T
Department of Cancer Cell Biology, Harvard School of Public Health, Boston, Massachusetts, MA 02115, USA.
Oncogene. 2002 Jun 20;21(27):4231-6. doi: 10.1038/sj.onc.1205528.
Promoter methylation is an important pathway in transcriptional silencing of known and candidate tumor suppressor genes in Head and Neck Squamous Cell Carcinoma (HNSCC). In order to study the association of tumor suppressor gene promoter methylation in HNSCC with patient clinical characteristics, especially alcohol consumption and tobacco smoking, we examined promoter methylation of the p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A genes using methylation-specific PCR (MSP) in 80 patients. The prevalence of p16(INK4a), DAP-kinase, E-Cadherin, and RASSF1A promoter methylation was 26/80 (32.5%), 19/80 (23.8%), 29/80 (36.3%), 6/80 (7.5%) respectively. In 48 cases (60%), at least one of these promoters was methylated. There was a significant association of methylation of any of these genes and ever smoking (P=0.006). p16(INK4a) gene promoter methylation was associated with a younger age of smoking initiation (P<0.03); E-Cadherin promoter methylation was associated with an increased number of pack years smoked (P<0.03). We also found an association of methylation of any gene and T status (OR=2.7, P<0.05). Tumors with p16(INK4a) methylation were significantly less likely to show lymph node metastasis (P<0.001). DAP-kinase promoter methylation was significantly associated with lymph node metastasis and this relationship was dependent upon p16(INK4a) promoter methylation status. Our results suggest that, in HNSCC, promoter methylation of these four genes accumulates with increasing tumor size. This may reflect distinct pathways of somatic inactivation leading to cancer; additional larger studies are needed to further investigate this possibility. Tobacco smoking may play an important role in both the occurrence of promoter methylation as well as delineating the precise pathway that eventually results in a tumorigenic phenotype.
启动子甲基化是头颈部鳞状细胞癌(HNSCC)中已知和候选肿瘤抑制基因转录沉默的重要途径。为了研究HNSCC中肿瘤抑制基因启动子甲基化与患者临床特征(尤其是饮酒和吸烟)之间的关联,我们使用甲基化特异性PCR(MSP)检测了80例患者中p16(INK4a)、DAP激酶、E-钙黏蛋白和RASSF1A基因的启动子甲基化情况。p16(INK4a)、DAP激酶、E-钙黏蛋白和RASSF1A启动子甲基化的发生率分别为26/80(32.5%)、19/80(23.8%)、29/80(36.3%)、6/80(7.5%)。在48例(60%)患者中,这些启动子中至少有一个发生了甲基化。这些基因中任何一个的甲基化与曾经吸烟显著相关(P = 0.006)。p16(INK4a)基因启动子甲基化与开始吸烟的年龄较小相关(P < 0.03);E-钙黏蛋白启动子甲基化与吸烟包年数增加相关(P < 0.03)。我们还发现任何基因的甲基化与T分期相关(OR = 2.7,P < 0.05)。发生p16(INK4a)甲基化的肿瘤发生淋巴结转移的可能性显著降低(P < 0.001)。DAP激酶启动子甲基化与淋巴结转移显著相关,且这种关系取决于p16(INK4a)启动子甲基化状态。我们的结果表明,在HNSCC中,这四个基因的启动子甲基化随着肿瘤大小的增加而累积。这可能反映了导致癌症的体细胞失活的不同途径;需要更多更大规模的研究来进一步探究这种可能性。吸烟可能在启动子甲基化的发生以及确定最终导致致瘤表型的确切途径中起重要作用。